Phase 2 Study | BRAF-MEK inhibition in BRAF-mutated papillary craniopharyngiomas leads to tumor volume reduction

BRAF–MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Rare Brain Tumor Responds to Targeted Tumor Treatment with ‘Unprecedented’ Success – Mass General Brigham

Commentary on Twitter

Genetic analysis has shown the presence of activating BRAF mutations in 94% of papillary craniopharyngiomas. A phase 2 study showed partial response or better in 15 of 16 previously untreated patients. Read the full study: https://t.co/UOjerJ17s3

— NEJM (@NEJM) July 12, 2023